Acceptability of a New Paediatric Formulation of Hydroxycarbamide in Children With Sickle Cell Disease.
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This is a prospective, interventional, phase II, open-label, multicentre, national,
non-comparative study of a single administration of the new dispersible form of
hydroxycarbamide at the usual dose in children with sickle cell disease who are already
treated with the current form of hydroxycarbamide (Siklos® 100 mg and/or 1000 mg film-coated
tablets).